Key Insights

Highlights

Success Rate

87% trial completion (above average)

Published Results

56 trials with published results (21%)

Research Maturity

143 completed trials (54% of total)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 30/100

Termination Rate

8.3%

22 terminated out of 266 trials

Success Rate

86.7%

+0.1% vs benchmark

Late-Stage Pipeline

36%

95 trials in Phase 3/4

Results Transparency

39%

56 of 143 completed with results

Key Signals

56 with results87% success22 terminated

Data Visualizations

Phase Distribution

198Total
Not Applicable (18)
Early P 1 (3)
P 1 (37)
P 2 (45)
P 3 (26)
P 4 (69)

Trial Status

Completed143
Unknown59
Terminated22
Recruiting15
Not Yet Recruiting10
Withdrawn9

Trial Success Rate

86.7%

Benchmark: 86.5%

Based on 143 completed trials

Clinical Trials (266)

Showing 20 of 20 trials
NCT06550128Phase 2Active Not RecruitingPrimary

Study to Evaluate the Efficacy and Safety of AHB-137 Injection in Participants With Chronic Hepatitis B (CHB).

NCT06923280Not ApplicableRecruitingPrimary

Sequential PEG-IFN for HBV After Ending RNA-targeted Regimens

NCT04782375Phase 4CompletedPrimary

Safely Discontinue Antiviral Treatment in Patients With Chronic Hepatitis B

NCT04749368Phase 2CompletedPrimary

Study to Investigate the Safety and Efficacy of BRII-835 and BRII-179 Combination Therapy Treating Chronic Hepatitis B Virus (HBV) Infection

NCT07716384Not Yet Recruiting

Wearable Patch Ultrasound Probe for Diagnosis of Liver Stiffness

NCT07696520Phase 2Not Yet RecruitingPrimary

Bepirovirsen Liver Biopsy Study

NCT05630807Phase 3Completed

Study of Bepirovirsen in Nucleos(t)Ide Analogue-treated Participants With Chronic Hepatitis B (B-Well 1)

NCT05630820Phase 3Completed

Study of Bepirovirsen in Nucleos(t)Ide Analogue-treated Participants With Chronic Hepatitis B (B-Well 2)

NCT02995252Active Not RecruitingPrimary

The HOPE Study: Characterizing Patients With Hepatitis B and C

NCT07654283Phase 2Not Yet RecruitingPrimary

Study of AHB-137 in Chronic Hepatitis B (CHB) Participants in North America and Europe Regions

NCT07370207Phase 2RecruitingPrimary

Phase 2 Study of AHB-137 in HBeAg Negative Chronic Hepatitis B (CHB) Participants in Asia Pacific Region

NCT07617194Phase 1Not Yet RecruitingPrimary

Study of AHB-171 in Chronic Hepatitis B Participants

NCT06115993Phase 1CompletedPrimary

A Study to Evaluate the Safety and Efficacy of AHB-137 in Healthy Participants and HBeAg-negative Chronic Hepatitis B (CHB) Patients

NCT07555340Active Not RecruitingPrimary

A Real-World Study on the Efficacy and Safety of Pradefovir Mesylate Tablets in the Treatment of Chronic Hepatitis B

NCT07553767Early Phase 1Not Yet Recruiting

Efficacy and Safety of Pegylated Interferon Alpha-2β in Patients With Hepatitis B-related Hepatocellular Carcinoma After Radical Resection

NCT07298577Not ApplicableEnrolling By Invitation

Use of Gender, Age, Alfa-fetoprotein (AFP), and Des-gamma-carboxyprothrombin (PIVKA-II) or GAAD Score in Addition to Ultrasound for Surveillance of People At-risk for Developing Hepatocellular Carcinoma in Asia in Order to Detect Early Liver Cancer

NCT04856085Phase 2CompletedPrimary

Study of VIR-2218, VIR-3434, and/or PEG-IFNα in Subjects With Chronic Hepatitis B Virus Infection

NCT07544121Not ApplicableNot Yet RecruitingPrimary

Effect of Babao Dan Capsule Combined With Antiviral Therapy on the Incidence of Hepatocellular Carcinoma in Patients With Hepatitis B-related Cirrhosis

NCT07491848RecruitingPrimary

Oral-Periodontal Evaluation and Assessment of Oral Fluid Biomarkers in Patients With Hepatitis B+D

NCT07481032Not ApplicableNot Yet Recruiting

Effect of Fufang Biejiaruangan Combined With Antiviral Therapy on the Incidence of Hepatocellular Carcinoma in Patients With Hepatitis B-related Cirrhosis: A Multicenter, Randomized, Placebo-controlled Study

Scroll to load more

Research Network

Activity Timeline